Ns Pharma, Inc., A Wholly Owned Subsidiary Of Nippon Shinyaku Co., Ltd, Announced That The First Patient Enrollment In A Phase 2 Clinical Study Of Ns-018 (Ilginatinib), An Investigational Treatment For Myelofibrosis (Mf), A Rare And Incurable Blood Cancer.The Phase 2B Study Is An Open-Label, Multicenter, Randomized, Controlled, 2-Arm Study To Assess The Efficacy And Safety Of Orally Administered Ns-018 Versus Best Available Therapy In Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/
